"rationale","label","id","instanceType","name","uuid:ID","description"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign_1","StudyDesign","Study Design 1","9a502194-2383-4a3d-91b7-a92b26d29a01","The main design for the study"
